Inhaled epoprostenol vs inhaled nitric oxide for refractory hypoxemia in critically ill patients

We found no difference in efficacy and safety outcomes when comparing iNO and iEPO in hypoxic, critically ill patients. Inhaled epoprostenol is associated with less drug expenditure than iNO.